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To assess the role of interleukin (IL)-33 and ST2, the receptor for IL-33, in the 
pathogenesis of systemic juvenile idiopathic arthritis (s-JIA), we sequentially 
measured the serum levels of IL-33 and soluble ST2 (sST2) in patients with s-JIA 
and determined their correlation with measures of disease activity and severity. 
Twenty-four patients with s-JIA, 5 with rheumatoid factor positive polyarticular JIA 
(RF + poly-JIA), and 20 age-matched healthy controls (HCs) were analyzed. IL-
33 and sST2 levels were quantiﬁed in serum by enzyme-linked immunosorbent 
assays. Serum IL-33 levels in most patients with active s-JIA were below the 
lowest detection limit. Serum IL-33 levels in patients with RF + poly-JIA were 
signiﬁcantly higher than those in patients with s-JIA and HC. Serum sST2 levels 
in patients during the active phase of s-JIA were much higher than those in 
patients with poly-JIA and HC. Serum sST2 levels in patients with s-JIA were 
signiﬁcantly elevated even in the inactive phase, when other clinical parameters 
were normalized. Serum sST2 levels correlated positively with the clinical 
parameters of disease activity. These ﬁndings indicate that ST2 may be an 
important mediator in s-JIA. Serum sST2 levels in patients with s-JIA correlated 








Juvenile idiopathic arthritis (JIA) is a heterogeneous and multi- factorial 
autoimmune disease characterized by chronic joint inﬂammation in children with 
onset ages younger than 16 years. It is the most common chronic rheumatic 
disease of childhood and an important cause of short-term and  long-term  
disability. JIA has different subtypes that are deﬁned based on the number of 
joints involved in the ﬁrst 6 months of disease and the extra- articular involvement 
[1]. The subtypes include oligoarticular JIA (<5 joints), polyarticular JIA (poly-JIA) 
(P5 joints) and systemic JIA (s-JIA). s-JIA is deﬁned by arthritis with spiking fever 
persisting for more than 2 weeks and at least one of the following clinical features 
of systemic inﬂammation: skin rash, lymphadenopathy, hepatosplenomegaly or 
serositis (pleuritis or pericarditis) [1]. Markedly distinct clinical and laboratory 
features of poly-JIA and s-JIA indicate their distinct pathogenesis and 
immunologic abnormality. The pathogenesis of JIA is not fully understood but 
likely includes genetic and environmental factors which show some commonality 
to various adult rheumatic diseases e.g. rheumatoid factor positive (RF+)poly-JIA 
and adult RA, s-JIA and adult Still’s disease [2,3]. High numbers of autoreactive 
T cells within the joint of poly-JIA patients indicate an antigen-driven activation of 
the adaptive immune system [4]. However, the typical clinical signs of s-JIA are 
rather associated with granulocytosis, thrombocytosis and increase of acute-
phase reactants in the peripheral blood, indicating an uncontrolled activation of 
the innate immune system. Recent studies have shown that inﬂammatory 
cytokines, including interleukin (IL)-1, IL-6, and IL-18, play pathogenic roles in the 
dis- ease processes of s-JIA [5]. Furthermore, the treatment with bio- logic 
therapies to block these cytokines has a dramatic effect for s-JIA patients [5]. 
These ﬁndings indicate that autoinﬂammatory mechanisms seem to play a major 
role in the pathogenesis of s-JIA.  
Macrophage activation syndrome (MAS) is a severe, potentially life-threatening 
complication of s-JIA. It is clinically characterized by    fever, 
hepatosplenomegaly, lymphadenopathy, profound depression of all three blood 
cell lines, deranged liver function, intravascular coagulation, and central nervous 
system dysfunction [6]. The excessive activation and proliferation of T 
lymphocytes and macrophages are observed in MAS. Massive hypercytokinemia 
is strongly associated with the pathogenesis of MAS [6]. 
Interleukin-33 (IL-33) is a novel IL-1 family cytokine that plays a major role in 
inﬂammatory, infectious, and autoimmune diseases [7,8]. IL-33 was identiﬁed as 
the ligand for the orphan receptor, ST2 [9]. ST2 molecule is a member of the IL-
1 receptor family that exists in two forms: a transmembrane full-length form and 
a soluble, secreted form (sST2) [10]. sST2 acts as a decoyreceptor for IL-33 [11]. 
IL-33 affects the function of cells that express ST2 molecule. IL- 33 polarizes 
naive T cells to produce Th2-associated cytokines IL-4, IL-5 and IL-13 [7] and 
functions as a chemoattractant for Th2 cells in vitro and in vivo [12], but also 
induces secretion of proinﬂammatory cytokines and chemokines by mast cells 
[13], basophils [14] and Th1 type cytokines from NK and NKT cells [14,15]. Also, 
IL-33 ampliﬁes polarization of alternatively activated M2 macro- phages [16], 
induces maturation of dendritic cells [17] and may promote Th1-type response 
[18]. 
Besides the regulation of disease outcome through the modulation of Th1/Th2 
bias, there is some evidence to suggest that ST2 may also be involved in 
inﬂammatory responses. A previous report revealed that the sST2-Fc fusion 
protein suppressed inﬂammatory responses that were induced by 
lipopolysaccharide (LPS) both in vitro and in vivo [19]. In normal conditions, the 
serum concentration of sST2 is below the detectable level, but elevated level of 
sST2 has been reported in patients with autoimmune diseases [20], asthma [11], 
idiopathic pulmonaryﬁbrosis [23]. The sST2 levels were found to correlate with 
the activity and severity of these conditions [21–24]. 
In this way, IL-33 and ST2 have important functions in host defense, immune 
regulation, and inﬂammation. However, its role in the pathogenesis of s-JIA and 
a causal relationship with disease activity are still unclear. To assess the role of 
IL-33 and ST2, in the pathogenesis of s-JIA, we sequentially measured serum 
levels of IL-33 and sST2 in patients with s-JIA and determined their correlation 




2.1. Patients and samples 
 
Serum samples were obtained from 24 patients with s-JIA, 5 patients with RF 
+ poly-JIA, and 20 age- and sex-matched healthy controls (HC) [age, s-JIA: 8.9 
± 6.5 years and HC: 10.5 ± 7.4 years]. Eleven patients were evaluated 
longitudinally on a second occasion when their disease was in an inactive phase. 
Four patients with MAS were evaluated serially from the phase of MAS to 
remission. The clinical characteristics of the patients with s-JIA are shown in Table 
1. 
Diagnoses of s-JIA and RF + poly-JIA were based on the International League 
of Associations for Rheumatology criteria [1]. MAS was diagnosed based on the 
combination of cytopenias affecting at least two cell lines, coagulopathy, and liver 
dysfunction, according to the guidelines proposed by Ravelli et al. [24]. The 
criteria deﬁning the active phase of s-JIA were active arthritis, fever, rash, 
hepatosplenomegaly, generalized lymphadenopathy, and serositis as well as 
increased erythrocyte sedimentation rates and C- reactive protein (CRP) levels. 
The criteria for the inactive phase of s-JIA on medication were as follows: the ﬁrst 
time after the recovery from MAS with no clinical symptoms that were observed 
in the active phase, as well as normal erythrocyte sedimentation rates (<5 mm/h) 
and CRP levels (<0.1 mg/dL). The criterion for remission of patients with s-JIA on 
medication was six continuous months of inactive disease while on medication 
[25]. 
Serum was separated from cells, divided into aliquots, frozen, and stored at 
80 °C until use. This study was approved by the Institutional Review Board at 
Kanazawa University, and all specimens were used after informed consent was 
obtained. 
 
2.2. Quantiﬁcation of serum cytokines 
 
Levels of IL-33 were evaluated by enzyme-linked immunosorbent assay 
(ELISA) according to the manufacturer’s instructions (Human IL-33 DuoSet⑧ 
ELISA Development System, R&D Systems, Inc., Minneapolis, MN, USA). Levels 
of sST2 were evaluated by ELISA according to the manufacturer’s instructions 
(Human ST2/ IL-1R4DuoSet⑧  ELISA Development System, R&D Systems, 
Inc., Minneapolis, MN, USA). The range of ELISA for IL-33 was from 3.6 to 1500 
pg/mL. The range of ELISA for sST2 was from 31.5 to 2000 pg/mL. RF positivity 
did not interfere with the ELISA assay. 
 
2.3. Statistical analysis 
 
Within-group comparisons were analyzed by the Mann–Whitney test. 
Correlations were expressed using the Spearman rank correlation coefﬁcient. For 




3.1. Serum levels of IL-33 and sST2 
 
We determined the serum levels of IL-33 and sST2 in patients with s-JIA and 
compared them with the levels in patients with RF + poly-JIA and HC. Serum IL-
33 levels in most patients with active s-JIA were found to lie below the lowest 
detection limit of the assay (Fig. 1A). IL-33 was detected in 4 out of 24 s-JIA 
patients (17%) 9 out of 20 control subjects (45%). The differences in the serum 
IL-33 levels among these s-JIA patients (median, 68; range, 4–702 ng/mL), and 
HC (median, 50; range, 4–169 ng/mL) were not statistically signiﬁcant. On the 
other hand, serum IL-33 levels in RF + poly-JIA patients (median, 155; range, 61–
533 ng/mL) were signiﬁcantly elevated compared with those in active s-JIA 
patients and HC (P < 0.01). These patients did not demonstrate symptoms that 
were suggestive of allergic diseases or atopy at the time of the study. 
In contrast, serum sST2 levels in patients with MAS (median, 19,500; range, 
3680–61,000 pg/mL) and in patients in the active phase of s-JIA  (median, 2205; 
range, 496–43,000 pg/mL) were much higher than those in patients with RF + 
poly-JIA (577, 338– 1120 pg/mL) and HC (354, 102–1052 pg/mL)(Fig. 1B). Serum 
sST2 levels in patients with s-JIA were signiﬁcantly elevated even in the inactive 
phase (839, 360–4550 pg/mL), and they normalized in the remission phase (402, 
267–512 pg/mL). The serum sST2 levels in RF + patients were not signiﬁcantly 
different compared to HC. 
 
3.2. Markedly elevated concentrations of serum sST2 in patients in the 
active phase of s-JIA and MAS 
 
To investigate the relevance of sST2 to the pathogenesis of s-JIA and MAS, 
serum sST2 levels were serially monitored in four cases of s-JIA (Fig. 2). The 
serum sST2 levels were both rapidly and markedly elevated when the 
complication of MAS occurred, but gradually reduced after such manifestations 
disappeared with corticosteroid and cyclosporine therapy. Even a few weeks after 
normalization of the indicators of an inﬂammatory reaction, such as lactate 
dehydrogenase (LDH) levels, the sST2 levels were still well above the values of 
HCs. Disease relapse of s-JIA with MAS was complicated in 1 case (Fig. 2A) 
during this phase of high serum sST2 levels. 
 
3.3. Correlation between serum sST2 and measures of disease activity 
in the clinical course of four cases of s-JIA 
 
Because the levels of serum CRP, aspartate aminotransferase, LDH, and 
ferritin are clinically used as indicators of disease activity in s-JIA, their 
concentrations were compared with those of sST2. The serum sST2 levels 
correlated positively with each of these indicators (Fig. 3A–D). However, even 
during the clinically inactive phase after remission from MAS, the serum sST2 




In this study, we demonstrated that serum sST2 levels in patients with s-JIA 
were markedly elevated during the active phase of s-JIA and correlated with 
measures of disease activity. These ﬁndings indicate that serum sST2 levels may 
have a potential role as a promising indicator of disease activity. Furthermore, 
serum sST2 levels in patients with s-JIA were signiﬁcantly elevated even during 
the inactive phase, and they were normalized in the remission phase. High serum 
sST2 levels persisted in patients for about six continuous months of inactive 
disease while on medication. These ﬁndings support the appropriateness of the 
Wallace criteria for the clinical remission of JIA (six continuous months of inactive 
disease while on medication) [25]. In this way, monitoring serum sST2 levels may 
be also useful for assessing treatment effects and the clinical remission of s-JIA. 
Elevated IL-33 levels were infrequently observed in s-JIA patients, and their 
levels were found to be comparable to those of controls. Serum IL-33 levels were 
not found to be related to sST2 levels or the disease activity of s-JIA. It is possible 
that IL-33 may have formed immune complexes with sST2 or was downregulated 
by sST2 through negative regulatory mechanisms because sST2 functions as a 
negative regulator and is an antagonistic decoy receptor for IL-33 [11]. 
Other possibility is that biological action of increased sST2 in serum might not 
be mediated via IL-33 neutralization. There is some evidence to suggest that 
sST2 may also be involved in inﬂammatory responses. A previous report revealed 
that sST2 suppressed the expression of toll-like receptor (TLR) 1 and 4 [19] and 
that this may contribute to the anti-inﬂammatory effects of sST2 in macro- phages. 
The role of TLRs in s-JIA has been consistently demonstrated [26]. For example, 
signaling through the IL-1 and IL-18 receptors shares the downstream portion of 
the TLR4 signaling pathway, and IL-1 and IL-18 provide positive feedback loops 
that further contribute to the perpetuation of the inﬂammatory responses in s-JIA 
[26]. These ﬁndings indicate that sST2 may have a role in resolving inﬂammatory 
responses by regulating macro- phage activation in the pathogenesis of s-JIA. 
Furthermore, sST2 may provide a novel approach for treating s-JIA by inhibiting 
the release of proinﬂammatory cytokines. In fact, a previous study revealed the 
therapeutic effects of sST2-Fc in a murine model of collagen-induced arthritis [27]. 
The alternative activation of monocytes and macrophages may play a role in 
resolving inﬂammatory responses in the pathogenesis of s-JIA. It has been well 
described that IL-33 and ST2 are modulators of inﬂammation and mediate Th2 
immune responses [12]. IL-33 has been shown to induce the production of Th2 
cytokines [7] and to possess a chemoattractant effect for human Th2 cells [12]. 
In this study, serum sST2 levels in patients with s-JIA were elevated not only in 
the active phase but also in the inactive phase. These ﬁndings indicate that sST2 
may have a role in resolving inﬂammatory responses by promoting monocyte 
differentiation into M2 macrophages through Th2 immune responses in the 
pathogenesis of s-JIA, as previously reported [16,28]. 
In this study, serum IL-33 levels were signiﬁcantly elevated in RF + poly-JIA 
patients. A previous study revealed that serum IL- 33 levels were elevated in sera 
and synovial ﬂuid samples from patients with rheumatoid arthritis (RA), and the 
levels correlated with disease activity [29–37]. IL-33 is produced mainly in 
inﬂamed joints [29]. A recent study showed that the serum IL-33 levels were 
correlated with the production of IgM and RA-related autoantibodies, including 
RF and anticitrullinated protein antibodies [30]. Our results were consistent with 
these ﬁndings. Although the number of RF + poly-JIA patients in this study was 
small and a larger study may help deﬁne the true diagnostic value of these 
markers, our study indicates that IL-33 may play an important role in the joint 
inﬂammation of human RF + poly-JIA. 
We have not determined the source of IL-33 and sST2 in patients with s-JIA in 
this study. A previous study showed that various cell types, including smooth 
muscle cells, epithelial cells, ﬁbroblasts, keratinocytes, dendritic cells, and 
activated macro- phages, express IL-33 mRNA [7]. IL-33 mRNA was induced in 
ﬁbro- blasts and keratinocytes by stimulation with tumor necrosis factor (TNF)-α 
and IL-1 [7]. However, IL-33 mRNA was only modestly induced in dendritic cells 
and macrophages by stimulation with LPS [7]. Furthermore, the expression of IL-
33 mRNA has been found in endothelial cells from chronically inﬂamed tissues 
from patients with Crohn’s disease and RA [38]. sST2 was induced in ﬁbroblasts, 
macrophages, and monocytes by stimulation with LPS, TNF-α , or IL-1 [39]. 
Furthermore, previous studies showed that epithelial and endothelial cells, and 
cardiac myocytes can secrete sST2 [40,41]. These ﬁndings indicate that sST2 
and/or IL-33 may be re- leased from activated macrophages, dendritic cells, or 
endothelial cells from inﬂamed tissues in patients with s-JIA. 
sST2 levels obtained in HC were again 10-fold higher than many other papers 
measuring sST2 in serum. Some reasons of this discrepancy might be due to the 
difference of kit and/or operation difference. 
The limitation of the present study was the small number of s-JIA patients. A 
larger study may help to deﬁne the true diagnostic value of these markers. 
Despite this limitation, our results indicate that ST2 may be an important mediator 
in s-JIA. Serum sST2 levels in s-JIA patients correlated with disease activity, 
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Table 1 
Clinical characteristics of patients with systemic juvenile idiopathic arthritis during 
the active phase.  
CRP, C-reactive protein; AST, aspartate aminotransferase; LDH, lactate 
dehydrogenase; PSL, prednisolone; MTX, methotrexate. 
Figure legends 
Fig. 1.  
Serum levels of IL-33 (A) and sST2 (B) in patients with s-JIA.  
Bars represent median values. Statistically signiﬁcant differences between each 
patient group are shown as *P < 0.05, **P < 0.01, and ***P < 0.001.  
IL, interleukin; sST2, soluble ST2; s-JIA, systemic juvenile idiopathic arthritis; RF 
+ poly-JIA, rheumatoid factor + polyarticular juvenile idiopathic arthritis; HC,
healthy control.
Fig. 2.  
Longitudinal assessment of serum sST2 levels and LDH in four patients with MAS. 
Changes in serum sST2 (solid lines) and LDH (dotted lines) levels are shown in 
the upper panels and the details of the therapeutic interventions are shown in the 
lower panels. Time points of blood draw are shown with arrows.  
sST2, soluble ST2; LDH, lactate dehydrogenase; M, MAS; A, active phase; I, 
inactive phase; R, remission; mPSL, methylprednisolone; DEX-P, 
dexamethasone palmitate; PSL, prednisolone; CyA, cyclosporine. 
Fig. 3.  
Positive correlations between serum sST2 levels and measures of disease 
activity, including the other cytokines, during the clinical course of s-JIA. (A, CRP; 
B, AST; C, LDH; D, ferritin).  
IL, interleukin; CRP, C-reactive protein; AST, aspartate aminotransferase; LDH, 
lactate dehydrogenase. 
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